VANCOUVER, British Columbia and SAN DIEGO, March 21, 2019 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing precise cancer therapeutics by targeting essential kinases, announced today the appoint… […]
Conference call scheduled for 4:30 p.m. ET today- Additional VK2809 Phase 2 Data to be Presented at EASL 2019; Results Demonstrate Promising Efficacy at Doses as Low as 5 mg Daily- Initiation of Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Planned… […]
SAN DIEGO and VANCOUVER, British Columbia, March 13, 2019 /PRNewswire/ — Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company,” “We” or “Sophiris”), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in la… […]
— Preliminary results from the Phase 2 TRANSCEND study of the hepcidin mimetic PTG-300 for the treatment of beta thalassemia expected in the second half of 2019 —- U.S. Investigational New Drug (IND) filing by Janssen to support a Phase 2 study of o… […]
– NBI-74788 Achieved Study Goals and Demonstrated Reductions in Key Disease Biomarkers Exceeding Predetermined Threshold for Proof-of-Concept- Based on Interim Results, Company Plans to Meet with FDA to Discuss the Registration Program in Adult and Ped… […]
– Bunionectomy Results Complement Opioid-Free Results from the Previously Reported Hernia Repair Study –
SAN DIEGO, March 11, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving … […]
SAN DIEGO, March 5, 2019 /PRNewswire/ — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the following inv… […]
SAN DIEGO, March 4, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet … […]
SAN DIEGO, March 4, 2019 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in two upcoming investor conferences.
The 39th Annual Cowen Healthca… […]
SAN DIEGO, Feb. 28, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full-year ended December 31, 2018.
“Mirati made great progress… […]